MTOR and autoimmune lymphoproliferative syndrome: This is the case in APDS patients displaying hyperactive PI3K/mTOR signaling pathways [133, 134] and in ALPS‐FAS patients where defective FAS signaling results in increased PI3K/AKT/mTOR [2].